ADPT

26.27

2.98% 0.76

Vorhandelsmarkt: 26.20 -0.07 -0.27%

Adaptive Biotechnologies Corp (ADPT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose

Schlusskurs vom Vortag:

$25.51

Offen:

$25.66

24-Stunden-Volumen:

1.16M

Relative Volume:

0.73

Marktkapitalisierung:

$4.19B

Einnahmen:

$295.41M

Nettoeinkommen (Verlust:

$-49.64M

KGV:

-80.24

EPS:

-0.3274

Netto-Cashflow:

$-29.54M

1W Leistung:

+7.58%

1M Leistung:

-10.74%

6M Leistung:

+84.87%

1J Leistung:

+53.45%

1-Tages-Spanne:

$0.00

1-Wochen-Bereich:

$23.82

$26.45

52-Wochen-Spanne:

$12.00

$30.74

Adaptive Biotechnologies Corp Stock (ADPT) Company Profile

Firmenname

Adaptive Biotechnologies Corp

Sektor

Healthcare (1053)

Branche

Diagnostics & Research (44)

Telefon

206-659-0067

Adresse

1165 EASTLAKE AVE E, SEATTLE, WA

Mitarbeiter

624

Twitter

@adaptivebiotech

Nächster Verdiensttermin

2026-11-04

Neueste SEC-Einreichungen

ADPT's Discussions on Twitter

Compare ADPT vs TMO, DHR, NTRA, A, IQV

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ADPT Adaptive Biotechnologies Corp	26.27	4.19B	295.41M	-49.64M	-29.54M	-0.3274
TMO Thermo Fisher Scientific Inc	684.89	253.24B	45.20B	6.87B	6.75B	18.19
DHR Danaher Corp	232.97	163.77B	24.78B	3.68B	5.29B	5.1743
NTRA Natera Inc	404.90	58.36B	2.50B	-226.32M	71.51M	-1.6412
A Agilent Technologies Inc	175.96	49.61B	7.23B	1.41B	1.09B	4.979
IQV Iqvia Holdings Inc	273.60	45.03B	16.63B	1.39B	2.12B	8.0674

Adaptive Biotechnologies Corp Stock (ADPT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-12-02	Fortgesetzt	Morgan Stanley	Equal-Weight
2025-09-30	Eingeleitet	Guggenheim	Buy
2025-06-18	Eingeleitet	Craig Hallum	Buy
2025-03-21	Hochstufung	Goldman	Neutral → Buy
2023-07-05	Fortgesetzt	JP Morgan	Overweight
2023-01-05	Eingeleitet	Scotiabank	Sector Outperform
2022-12-21	Hochstufung	Piper Sandler	Neutral → Overweight
2022-08-25	Eingeleitet	Credit Suisse	Underperform
2022-06-03	Eingeleitet	Piper Sandler	Neutral
2022-02-16	Bestätigt	BTIG Research	Buy
2022-02-16	Bestätigt	BofA Securities	Buy
2022-02-16	Bestätigt	Goldman	Neutral
2022-02-16	Bestätigt	JP Morgan	Overweight
2021-10-15	Fortgesetzt	Cowen	Outperform
2021-03-03	Herabstufung	Goldman	Buy → Neutral
2020-10-08	Fortgesetzt	BTIG Research	Buy
2020-09-09	Eingeleitet	Morgan Stanley	Equal-Weight
2020-06-03	Eingeleitet	Goldman	Buy
2019-07-23	Eingeleitet	BTIG Research	Buy
2019-07-22	Eingeleitet	BofA/Merrill	Buy
2019-07-22	Eingeleitet	Cowen	Outperform
2019-07-22	Eingeleitet	Goldman	Neutral
2019-07-22	Eingeleitet	Guggenheim	Buy
2019-07-22	Eingeleitet	William Blair	Outperform

Alle ansehen

Adaptive Biotechnologies Corp Aktie (ADPT) Neueste Nachrichten

Oct 16, 2026

Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 14 October - Investing.com Nigeria

Oct 16, 2026

Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 14 October - Investing.com UK

Oct 16, 2026

COO sold 35,643 shares and exercised options at $12.14 at Adaptive Biotechnologies (ADPT). - Stock Titan

Oct 16, 2026

Oct 13, 2026

Form 4 Adaptive Biotechnologies Corp: Julie Rubinstein (President and COO) For: 9 October - Investing.com Nigeria

Oct 13, 2026

The COO exercised options and sold 35,643 Adaptive Biotechnologies (ADPT) shares. - Stock Titan

Oct 13, 2026

Oct 08, 2026

At $12.14 per share, Adaptive Biotechnologies (ADPT) COO exercised options on each of three share-sale dates. - Stock Titan

Oct 08, 2026

An officer sells 6,444 shares at $30 each under a trading plan at Adaptive Biotechnologies (ADPT). - Stock Titan

Oct 08, 2026

Oct 06, 2026

Adaptive Biotechnologies Officer Susan Bobulsky Files to Sell 6,444 Shares Under 10b5-1 Plan - Kalkine Media

Oct 06, 2026

Officer Susan Bobulsky proposes selling 6,444 Adaptive Biotechnologies (ADPT) shares. - Stock Titan

Oct 06, 2026

Oct 05, 2026

Adaptive Biotechnologies COO Julie Rubinstein sells $1m in stock - Investing.com

Oct 05, 2026

Form 4 Adaptive Biotechnologies Corp For: 5 October By Investing.com - Investing.com Nigeria

Oct 05, 2026

Form 4 Adaptive Biotechnologies Corp For: 5 October By Investing.com - Investing.com UK

Oct 05, 2026

An officer exercises options and sells Adaptive Biotechnologies (ADPT) shares under a preset plan. - Stock Titan

Oct 05, 2026

A COO exercises $12.14 options and sells 35,643 Adaptive Biotechnologies (ADPT) shares. - Stock Titan

Oct 05, 2026

Oct 01, 2026

Adaptive Biotechnologies Officer Julie Rubinstein Files Form 144 to Sell 379,777 Shares - Kalkine Media

Oct 01, 2026

Options exercised over three months will supply an officer's planned sale at Adaptive Biotechnologies (ADPT). - Stock Titan

Oct 01, 2026

Sep 28, 2026

Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com - Investing.com Canada

Sep 28, 2026

Form 4 Adaptive Biotechnologies Corp For: 28 September By Investing.com - Investing.com South Africa

Sep 28, 2026

Sep 18, 2026

Adaptive Biotechnologies (ADPT) HR chief sells over 100,000 shares under preset plan - Stock Titan

Sep 18, 2026

Sep 17, 2026

Adaptive biotechnologies chief commercial officer sells $32,265 in shares. - Investing.com

Sep 17, 2026

Adaptive Biotechnologies (NASDAQ: ADPT) CCO sells shares under pre-set trading plan - Stock Titan

Sep 17, 2026

Sep 16, 2026

Adaptive Biotechnologies (ADPT) officer to sell 142K shares - Stock Titan

Sep 16, 2026

Sep 15, 2026

Officer at Adaptive Biotechnologies (NASDAQ: ADPT) plans sale of 1,195 shares - Stock Titan

Sep 15, 2026

Sep 02, 2026

Adaptive Biotechnologies (NASDAQ: ADPT) director reports stock gift, still holds 66,100 shares - Stock Titan

Sep 02, 2026